Osteotech appoints Dr Laurencin
This article was originally published in Scrip
Dr Cato Laurencin has been appointed to the board of the regenerative medicine company Osteotech (US). He is an orthopaedic surgeon and dean of the school of medicine at the University of Connecticut.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
The European Commission has extended the indications for Janssen’s Tremfya to include psoriatic arthritis, and those for BMS’s Opdivo to include gastroesophageal cancer.